The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, a clinical-stage ...
Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Plan to report an interim safety and efficacy update ...
Safusidenib demonstrated durable responses, with an ORR of 44% and 88% of patients were progression-free at 24 months Findings supported recent favorable interactions with FDA where alignment was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results